SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether patients with early disease progression (EDP), are cha...

詳細記述

書誌詳細
主要な著者: Evelien G. E. Hurkmans, Jan B. Koenderink, Jeroen J. M. W. van den Heuvel, Yvonne M. H. Versleijen-Jonkers, Melissa H. S. Hillebrandt-Roeffen, Johanne M. Groothuismink, Hanneke I. Vos, Winette T. A. van der Graaf, Uta Flucke, Grigor Muradjan, Hendrik W. B. Schreuder, Melanie M. Hagleitner, Han G. Brunner, Hans Gelderblom, Anne-Marie Cleton-Jansen, Henk-Jan Guchelaar, Eveline S. J. M. de Bont, Daan J. Touw, G. Jan Nijhoff, Leontien C. M. Kremer, Huib Caron, Rachael Windsor, Ana Patiño-García, Anna González-Neira, Federica Saletta, Geoff McCowage, Sumanth Nagabushan, Daniel Catchpoole, D. Maroeska W. M. te Loo, Marieke J. H. Coenen
フォーマット: 論文
言語:English
出版事項: Frontiers Media S.A. 2022-11-01
シリーズ:Frontiers in Pharmacology
主題:
osteosarcoma
pharmacogenetics
doxorubicin
L-type amino acid transporter 2
early disease progression
オンライン･アクセス:https://www.frontiersin.org/articles/10.3389/fphar.2022.1042989/full

インターネット

https://www.frontiersin.org/articles/10.3389/fphar.2022.1042989/full

類似資料